<i>XAGE‐1</i> mRNA Expression in Prostate Cancer and Antibody Response in Patients

Koizumi, Fumihito; Noguchi, Yuji; Sakaguchi, Takashi; Nakagawa, Kazuhiko; Sato, Kimiyasu; Eldib, Ali Mohamed Ali; Nasu, Yasutomo; Kumon, Hiromi; Nakayama, Eiichi

doi:10.1111/j.1348-0421.2005.tb03751.x

Cited by 12 publications

(17 citation statements)

References 16 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the basis of the immunocytochemical results Shibayama and Koizumi (3,13) confirmed that normal human prostate epithelial cells specifically express TrkA, but not TrkB or TrkC receptors. Weeraratna et al (14) further demonstrated that TrkA is homogeneously expressed in 60% of primary prostate cancers and 80% of metastatic sites in untreated patients.…”

Section: Discussionmentioning

confidence: 92%

A possible role of BDNF in prostate cancer detection

Bronzetti¹,

Artico²,

Forte³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

Abstract. Many studies have demonstrated that both normal and malignant prostate cells respond to a variety of growth factors, while several significant differences were found between normal and tumoural cells. The aim of this study was to focus on the localization and distribution of the immuno-reactivity for neurotrophins (NTs) and neurotrophin receptors (NTRs) in normal, hyperplastic and prostate cancer cells, obtained from 40 subjects. We studied samples obtained from 16 prostate cancer (PC, retropubic radical prostatectomy), 20 benign prostatic hyperplasia (BPH, supra-pubic prostatectomy) and normal peripheral prostate tissue from four fresh male cadavers. Samples were examined via immunohistochemical techniques in order to detect the expression of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and their own receptors TrkA, p75, TrkB and TrkC. We observed a high expression of BDNF and TrkB in PC and BPH, though no immuno-reactivity was found for p75. Low expression was reported by other NTs and NTRs in the normal peripheral prostate zone, BPH and PC. These data suggest a possible predictive role for NTs and NTRs, especially for BDNF and TrkB, in the diagnosis and/or management of prostate cancer. The absence of p75 expression confirms its supposed role in apoptotic phenomenon.

show abstract

Section: Discussionmentioning

confidence: 92%

A possible role of BDNF in prostate cancer detection

Bronzetti¹,

Artico²,

Forte³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Transfection with mRNA was shown to be able to present the antigen naturally to not only CD8 but also CD4 T cells (16,17,20). XAGE-1b mRNA was shown to be expressed frequently in non-small cell lung cancer (15/49, 31%), liver cancer (11/19, 58%), and prostate cancer (14/54, 24%), and less frequently in breast cancer (1/20, 5%) (12,18). In lung cancer, a high frequency of XAGE-1b mRNA expression was observed in adenocarcinoma (14/31, 45%) (18).…”

Section: Discussionmentioning

confidence: 99%

HLA‐DRB1*0410‐Restricted Recognition of XAGE‐1b₃₇‐48 Peptide by CD4 T Cells

Morishita¹,

Uenaka

Kaya

et al. 2007

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

XAGE‐1b belongs to cancer/testis (CT) antigens, and has been shown to be expressed frequently in lung cancers and to elicit an antibody response in patients with XAGE‐1b‐expressing tumors. In this study, we investigated an XAGE‐1b peptide recognized by CD4 T cells. CD4 T cells were purified from PBMC of a healthy donor and stimulated with pooled 25‐mer peptides overlapped with 15 amino acids spanning the entire XAGE‐1b protein. The generation of XAGE‐1b‐specific CD4 T cells was shown by IFN7 secretion assay. A CD4 T cell clone OHD1 was obtained by limiting dilution. OHD1 recognized two overlapping peptides, XAGE1‐b33–49 and XAGE‐1b37–52, by ELISPOT assay. A peptide XAGE‐1b38–46 which was included in both XAGE‐1b33–49 and XAGE‐1b37–52 was predicted to be a DRB1*0410‐restricted 9‐mer peptide by a computer‐based program. We identified the 12‐mer peptide XAGE‐1b37–48 as a new XAGE‐1b epitope restricted to HLA‐DRB1*0410.

show abstract

“…Furthermore, the dominant XAGE-1 isoform, XAGE-1b, is known to be able to stimulate the immune response of patients suffering from non-small cell lung or prostate cancer (22)(23)(24). In addition, antibody responses to recombinant L552S protein, an alternatively spliced isoform of XAGE-1, were observed in the pleural effusion fluids of lung cancer patients (25).…”

Section: Primermentioning

confidence: 99%

Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival

et al. 2010

View full text Add to dashboard Cite

Abstract. XAGE-1 is classified into the group of a new family of cancer-testis antigens (CTA) and has the four transcript variants of XAGE-1a, XAGE-1b, XAGE-1c and XAGE-1d. Immunohistochemistry was used to investigate the expression of XAGE-1 transcript variants in Chinese patients with hepatocellular carcinoma (HCC). Reverse transcriptionpolymerase chain reaction (RT-PCR) and real-time RT-PCR were used to analyze XAGE-1 gene expression, and XAGE-1 protein expression was examined by immunohistochemistry. Furthermore, the clinical correlation of XAGE-1 expression was analyzed. The expression of the XAGE-1 mRNA was investigated in the tissues of 96 HCC patients and all XAGE-1 isoforms were detected in these tissues. Three types of XAGE-1 transcript variants (XAGE-1b, XAGE-1c and XAGE-1d) showed high specific and frequent expression in HCC tissues, with the positive expression rate of XAGE-1b, XAGE-1c and XAGE-1d being 41.7% (40/96), 15.6% (15/96) and 26.0% (25/96), respectively. XAGE-1b was the dominant type, but none of the three were detected in adjacent non-HCC tissues. Only 2 cases of XAGE-1a mRNA expression were observed. Moreover, XAGE-1 protein was detected in 39 of 96 HCC patients, but none in the adjacent non-cancerous tissue and normal liver tissue. No relationship was found between the expression of XAGE-1 and clinical parameters, such as age, gender, tumor size, TNM staging, serum AFP level and infection with hepatitis virus. Patients with XAGE-1b-positive transcript variant exhibited shorter 2-year survival times. The high frequency and specificity of XAGE-1, particularly XAGE-1b, in HCC indicates that their products may predict the prognosis of HCC patients and be novel targets for antigen-specific immunotherapy to HCC.

show abstract

XAGE‐1 mRNA Expression in Prostate Cancer and Antibody Response in Patients

Cited by 12 publications

References 16 publications

A possible role of BDNF in prostate cancer detection

A possible role of BDNF in prostate cancer detection

HLA‐DRB1*0410‐Restricted Recognition of XAGE‐1b₃₇‐48 Peptide by CD4 T Cells

Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival

Contact Info

Product

Resources

About

XAGE‐1 mRNA Expression in Prostate Cancer and Antibody Response in Patients

Cited by 12 publications

References 16 publications

A possible role of BDNF in prostate cancer detection

A possible role of BDNF in prostate cancer detection

HLA‐DRB1*0410‐Restricted Recognition of XAGE‐1b37‐48 Peptide by CD4 T Cells

Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival

Contact Info

Product

Resources

About

HLA‐DRB1*0410‐Restricted Recognition of XAGE‐1b₃₇‐48 Peptide by CD4 T Cells